SGLT2i与合并心房颤动及糖尿病患者的心血管事件:TriNetX队列研究
本研究基于TriNetX国际电子病历数据库,纳入339792例合并心房颤动(AF)与2型糖尿病(T2DM)患者,其中32945例(9.70%)使用SGLT2i。经倾向性评分匹配后每组各17011例,随访3年,SGLT2i使用与卒中、痴呆、长程持续性AF、心力衰竭及全因死亡风险降低相关。
要点
- 合并AF与T2DM患者中,SGLT2i使用与卒中风险降低相关(校正HR 0.830,P<.001)。
- SGLT2i使用与痴呆、长程持续性AF、心力衰竭及全因死亡风险降低相关。
- 作者认为SGLT2i可考虑作为该人群的潜在一线治疗。
核心结论
- 在同时合并AF与T2DM的患者中,使用SGLT2i与卒中、痴呆、长程持续性AF、心力衰竭及死亡风险降低相关。
- 作者认为SGLT2i可考虑作为该人群的潜在一线治疗。
研究设计与样本
- 从TriNetX国际电子病历数据库中识别同时患有AF与T2DM的患者。
- 按是否使用SGLT2i分为2组,经倾向性评分匹配(PSM)按1:1分配。
- 共研究339792例AF合并T2DM患者,其中32945例(9.70%)为SGLT2i使用者。
- PSM后每组各纳入17011例,年龄68.4±7.9岁。
- 采用多变量Cox风险回归模型确定临床结局的风险比(HR)。
主要发现
- 随访3年后,SGLT2i治疗组卒中风险显著降低(校正HR 0.830,P<.001)。
- SGLT2i治疗组痴呆风险显著降低(校正HR 0.662,P<.001)。
- SGLT2i治疗组长程持续性AF风险显著降低(校正HR 0.917,P<.001)。
- SGLT2i治疗组心力衰竭风险显著降低(校正HR 0.833,P<.001)。
- SGLT2i治疗组全因死亡风险显著降低(校正HR 0.532,P<.001)。
临床怎么用
- 作者认为SGLT2i可考虑作为合并AF与T2DM患者的潜在一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) enhance cardiovascular outcomes in individuals with type 2 diabetes mellitus (T2DM). Whether such effects also occur in T2DM patients with atrial fibrillation (AF) remains unknown. We aimed to investigate SGLT2i use on cardiovascular outcomes in patients with concomitant AF and T2DM. METHODS: Patients with both AF and T2DM were identified from TriNetX, an international electronic medical record. Participants were divided into 2 groups according to their use of SGLT2i, at a 1:1 distribution through propensity score matching (PSM). The hazard ratio (HR) for clinical outcomes was determined using multivariate Cox hazards regression model. RESULTS: We studied 339 792 patients with AF and T2DM, with 32 945 (9.70%) SGLT2i users. Following PSM, 17 011 patients aged 68.4 ± 7.9 years were included in each group. After a 3-year follow-up, patients treated with SGLT2i showed significantly reduced risks of stroke (adjusted HR: 0.830, P < .001), dementia (adjusted HR: 0.662, P < .001), long-standing persistent AF (adjusted HR: 0.917, P < .001), heart failure (adjusted HR: 0.833, P < .001), and all-cause mortality (adjusted HR: 0.532, P < .001). CONCLUSION: The use of SGLT2i was associated with reduced risks of stroke, dementia, long-standing persistent AF, heart failure, and mortality in patients with both AF and T2DM. SGLT2i may be considered as a potential first-line therapy for this population.
引用
- Hsiao YY, Chen YY, Kuo MJ, et al. SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 39998428. doi:10.1210/clinem/dgae861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。